Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Peter Clark, MA, MD, FRCP: A Payer Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Aug

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Peter Clark, MA, MD, FRCP: A Payer Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies

Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL

Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors

Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment

County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults